Sudarshan Hebbar Acquires Shares in CALC
Sudarshan Hebbar, CALC's Chief Medical Officer, purchased 124,486 shares at $0.80 each.
Key Points
- Sudarshan Hebbar, Chief Medical Officer at CALC, bought 124,486 shares at $0.80 each, totaling $99,588.80 on June 25, 2026.
- CALC shares traded near $0.82 on Monday, with significant insider buying activity reported.
- Peer funds like Jane Street Group and Renaissance Technologies also adjusted their CALC holdings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Sudarshan Hebbar, the Chief Medical Officer at CALC, purchased 124,486 shares of the company at a price of $0.80 each, totaling $99,588.80. This transaction took place on June 25, 2026, and was not part of a pre-planned trading scheme.
Insider Buying and Selling at CalciMedica, Inc.
Besides Hebbar, several other insiders also bought shares of CALC on June 25, 2026. Rachel Leheny, the CEO, acquired 186,729 shares, while Robert Wilson purchased 1,182,621 shares. Fred Middleton and Eric Roberts, the Chief Business Officer, bought 248,972 and 186,729 shares respectively. All these transactions were conducted at the same price of $0.80 per share.
Other Institutional Activity in CALC
Several institutional investors have also been active with CALC shares. Jane Street Group increased its holdings by 159,312 shares, bringing its total to 178,515 shares valued at approximately $96,398, marking an 829.6% increase. Vanguard Capital Management opened a new position with 169,110 shares valued at $91,319. Renaissance Technologies added 39,775 shares, ending with 128,075 shares worth about $69,161, which is a 45.0% increase. 180 Wealth Advisors expanded its position by 94,650 shares, now holding 126,500 shares valued at $68,310, reflecting a 297.2% rise. Geode Capital Management increased its stake by 23,595 shares to a total of 123,382 shares, valued at $66,652, representing a 23.6% increase.
Analysts Set New Price Targets
Analysts have shown interest in CALC, with Oppenheimer maintaining a 'buy' rating and setting a price target of $10.00 on March 5, 2026. Previously, HC Wainwright & Co. reiterated a 'buy' rating with a $16.00 target on March 4, 2025. These ratings suggest continued confidence in CALC's potential.
Bottom Line
Sudarshan Hebbar's significant share purchase in CALC highlights insider confidence in the company's prospects. With both insiders and institutional investors actively buying, market participants are closely watching CALC. It's important to remember that these transactions are part of the company's historical data and may not reflect current positions.
Get CalciMedica, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CALC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.